Patterns of genetic expression associated to sensibility to doxorubicin versus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer

Trial Profile

Patterns of genetic expression associated to sensibility to doxorubicin versus docetaxel as neoadjuvant chemotherapy for locally advanced breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2011

At a glance

  • Drugs Docetaxel (Primary) ; Doxorubicin
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2011 Results published in Breast Cancer Research and Treatment.
    • 11 Aug 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top